The role of CSTF2 in gastric cancer: implications for therapy Authors: Liang Feng, Zhiguo Cao, Xiaoqi Shi, Wenhao Liu, Weiwei Xu, Changjun Yu, Jie Ning, Changyu Chen Published: 2025 ABSTRACT AbstractBackgroundGastric cancer is a fatal malignancy that is frequently diagnosed at an advanced stage worldwide, and current treatments are limited. The RNA-binding protein CSTF2 is associated with the prognosis of many cancers, but the role it plays in gastric cancer remains unknown.MethodsWe collected tissues of gastric cancer and adjacent ones paired adjacent non-tumor tissues at the First Affiliated Hospital of Anhui Medical University. CSTF2 expression was initially detected using immunohistochemistry and Western blotting, and its association with clinicopathological features was assessed. Knockdown of CSTF2 in gastric carcinoma cell models was conducted to examine the effect on cell proliferation, migration, and invasion. The mRNA stability of downstream targets was assessed by actinomycin D assay. Further RNA sequencing analysis revealed the downstream influential genes of CSTF2, especially TGM2. Afterwards, the function of TGM2 and its interactions with CSTF2 were further verified.ResultsThe production of CSTF2 was markedly higher in gastric cancer tissues compared to adjacent noncancerous tissues and showed a strong correlation with poor patient prognosis. CSTF2 inhibition significantly suppressed gastric cancer cell growth, proliferation, migration, and invasion. Mechanistically, CSTF2 knockdown accelerated the decay of TGM2 mRNA, indicating that CSTF2 post-transcriptionally stabilizes TGM2 transcripts. Further gene expression analysis revealed that TGM2 might serve as a key downstream effector of CSTF2. Ectopic expression of TGM2 partially rescued the inhibitory effect of CSTF2 deficiency on cell proliferation and colony formation.ConclusionsCSTF2 promotes gastric cancer progression by post-transcriptionally stabilizing TGM2 mRNA, and its overexpression is closely related to poor prognosis. The elucidated CSTF2–TGM2 regulatory axis may offer a promising and innovative therapeutic target for gastric carcinoma treatment.Keywords: CSTF2, Gastric cancer, TGM2, RNA-binding protein Introduction Gastric cancer ranks among the leading causes of cancer-linked fatalities worldwide, and despite the decline in its mortality and incidence rates in recent years, it still accounts for many newly diagnosed cancer cases and associated death toll [1]. Based on statistical data, there were approximately 1 million emerging gastric cancer diagnoses and roughly 784,000 deaths caused by gastric cancer globally in 2018 [2]. The total cases of gastric carcinoma is likely to increase further due to the ageing and growing population [3]. Typically, stomach cancer is diagnosed at an advanced stage [4]. The current common treatment includes surgical resection, adjuvant chemotherapy or radiotherapy [5, 6]. The latest treatment techniques also include methods, such as immunotherapy and targeted therapy [7]. However, current treatments for gastric cancer face multiple challenges, including a high recurrence rate, unfavorable prognosis, and a relatively low 5-year survival rate [8]. Therefore, it is crucial to conduct comprehensive research into the biochemical mechanisms driving gastric cancer and to identify potential therapeutic targets that could enhance survival rates and improve prognosis. Given that systemic inflammatory and metabolic markers such as the C-reactive protein/albumin ratio and visceral adipose tissue have been identified as independent prognostic factors in other cancers, such as colorectal cancer and breast cancer, similar mechanisms may also be involved in the carcinogenesis of gastric cancer [9, 10]. The high heterogeneity and complex cellular ecosystem of gastric cancer have posed significant challenges for understanding its pathogenesis and identifying effective targets. RNA sequencing has emerged as a powerful tool to deconvolute this complexity, enabling the identification of novel cell subtypes, signaling networks, and potential therapeutic targets at an unprecedented resolution [11, 12]. Applying such high-resolution techniques to gastric cancer is expected to reveal key drivers of tumor progression. Among various molecular regulators, RNA-binding proteins (RBPs) perform crucial functions in modulating the initiation, advancement and metastasis of cancer by modulating gene expression and cellular functions during transcription, splicing and translation [13–16]. One RBP of particular interest in this context is Cleavage Stimulation Factor Subunit 2 (CSTF2). CSTF2 is a component of the CSTF complex, playing a key role in mRNA processing by participating in post-transcriptional regulation and RNA binding. [17–19]Wang Zhang et al. reported that the manifestation of CSTF2 was markedly elevated in HCC (hepatocellular carcinoma) [20] and that elevated CSTF2 expression was strongly linked to unfavorable prognosis in patients with HCC. Meng-Hui Zhang also reported that CSTF2 was abundantly present in HCC and it promoted HCC by activating the PI3K/AKT/mTOR signal transduction network, promoting​ malignant progression [21]. In another study, CSTF2 was found to be overexpressed in glioblastoma tissues and showed a significant association with patient prognosis.CSTF2 inhibits tumor cell apoptosis by binding to and stabilizing the RNA that encodes Bcl-2-associated agonist of cell death (BAD) [22]. However, the intrinsic mechanism of CSTF2 in gastric cancer is not fully understood at present, and further in-depth studies are needed. In this research, we investigated in detail the protumorigenic role of CSTF2 for human gastric cancer. We noted a dramatic amplification in CSTF2 protein levels in the tissues of gastric carcinomas than in paracancerous tissues and was strongly correlated with a low overall survival (OS) and low progression-free survival (DFS). Our experimental results showed that decreasing CSTF2 expression considerably inhibited the proliferation of gastric cancer cells both in laboratory conditions and in living organisms, and RNA-seq revealed that CSTF2 downregulation contributed to substantial alterations in the expression of numerous downstream genes. Our analysis specifically targeted the Transglutaminase 2(TGM2) gene. By restoring TGM2 expression, we observed that the inhibitory impact of CSTF2 knockdown on cell proliferation and colony development was significantly reversed. These findings further confirmed the role of CSTF2 as a tumorigenic factor in human gastric cancer specimens. The results of this investigation present important clues for an in-depth understanding of the mechanism of gastric carcinogenesis and propose that CSTF2 could behave as a probable therapeutic suitable candidate for the management of gastric cancer. Materials and methods Tissue collection from gastric cancer patients In total, clinical information was obtained from 192 individuals diagnosed with gastric cancer between 2016 and 2017. Patients who were excluded if they had other diseases or had received specific treatments. Until December 2022, these cases were followed for a period of more than 5 years. Thirty-five couples of gastric cancerous specimens and peritumoral specimens were obtained from the Gastrointestinal Surgery Department of Gaoxin Hospital, the First Affiliated Hospital of Anhui Medical University, in 2022. The research was authorized by the Institutional Review Board of Anhui Medical University, as per the ethical standards of the World Medical Association (Declaration of Helsinki) was used to adhere strictly to the study protocol. All individuals were informed and gave their signature on an informed consent form before providing their information. Bioinformatics analysis Clinical and RNA-related data for 407 patients with STAD (including 375 tumour tissues and 32 normal tissues) in the TCGA database (https://portal.gdc.cancer.gov/) were analysed [23]. Analyses were completed and plotted by R software (version 4.3.1, www.Rproject.org). Immunohistochemistry The samples used in the immunohistochemical testing process were obtained from collected gastric cancer tissues that were processed through fixation, paraffin embedding, and sectioning. Immunohistochemically stained sections were observed by a professional pathologist using an Olympus microscope (Olympus, Japan), and stained images were obtained. Antibodies against CSTF2 (1:1000; sc-374373; Santa Cruz Biotechnology, USA) and TGM2 (1:1000; sc-21733; Santa Cruz Biotechnology, USA) were used. Western blot Protein expression levels of CSTF2 and TGM2 were analyzed in the BGC-823 and MKN-28 cell lines through Western blotting (WB). The detailed steps can be found in our previous article [24]. The process was performed using CSTF2 (1:1000, 26825-1-AP; Proteintech Group, USA), TGM2 (1:1000, 68006-1-Ig; Proteintech Group, USA) and β-actin (1:5000, 66009-1-Ig; Proteintech Group, USA) antibodies. Cell culture The BGC-823 and MKN-28 cell lines used in the study were extracted from the Shanghai Cell Bank (Shanghai, China) or ATCC (the American Type Culture Collection). Cells in culture were all kept in a humidified setting with 5% CO2 at 37 °C [25]. Cell function experiment We inoculated the cells in six-well plates, with 10,000 cells in each well, and recorded the number of cell proliferation for the next 5 days. The proliferation curve of the cells was plotted according to the change in cell number. The medium was replaced every 3 days for a period of 12 days. The cells were them collected and processed to assess cell colony formation. Xenograft experiments Male nude mice 5 weeks of age were selected as experimental subjects. Nude mice were assigned to each experimental group using a weight-stratified randomization protocol. Then, 5 × 106 tumour cells in media were mixed and injected into the lateral abdominal wall or tail vein of the mice. Tumour volume was measured every 5 days for 1 month after injection. Tumor volumes were measured by researchers blinded to the group allocation using digital calipers, with the longest diameter (L) and shortest diameter (W) of the tumors recorded. The volume was calculated using the formula: V = 0.5 × L × W2. RT‒qPCR The RNA levels of CSTF2 and TGM2 were analyzed by RT‒qPCR, with GAPDH serving as a control. The sequences of primers used during the experiments were as follows: CSTF2 (F: 5'-AGCTGAAGTTGACCGGAATG-3', R: 5'-GGAGCTGTGAGACCGAAGAA-3'), TGM2 (F: 5'-GCTGGAGAGAGTCACAGGAGGT-3', R: 5'-GGGACTTGCTGGAGGTTCTC-3'), and GAPDH (F: 5'-TGTGTCCGTCGTGGATCTGA-3', R: 5'-CCTGCTTCACCACCTTCTTGA-3'). RNA sequencing BGC-823-shCSTF2 and MKN-28-shCSTF2 cells were expanded, and RNA sequencing was completed by Genefund Biotechnology Company (Shanghai, China). Based on the RNA sequencing results, the genes downstream of CSTF2 were explored for potential roles in gastric cancer. Statistical analysis Cell proliferation information were analysed by two-tailed independent t test. OS/DFS were analysed within the gastric cancer patient group using Kaplan‒Meier curves. SPSS 16.0 software was utilized for analysis of statistical data, and the cutoff for statistical relevance was set at P < 0.05. Cell migration and invasion assay For the migration assay, 5 × 104 cells suspended in serum-free medium were seeded into the upper chamber. For the invasion assay, the upper chamber was pre-coated with Matrigel. Medium containing 20% fetal bovine serum was added to the lower chamber as a chemoattractant. After 24–48 h of incubation, cells that did not migrate or invade were removed from the surface of the upper membrane. Cells that migrated or invaded to the surface of the lower chamber were fixed with methanol, stained with 0.1% crystal violet, and then photographed and counted under a microscope. mRNA stability assay ​ To assess the half-life of TGM2 mRNA, we performed an actinomycin D chase assay. Actinomycin D was added to BGC-823 and MKN-28 cells to a final concentration of 10 μg/mL, so as to inhibit the transcription of nascent RNA. Cells were harvested at 0, 2, 4, 6, and 8 h after treatment for RNA extraction. The levels of TGM2 mRNA at different timepoints were detected by qPCR, with GAPDH used as the internal reference gene in the experiment. Results High CSTF2 expression is connected with an unfavorable prognosis for patients with gastric cancer Initial pancancer examination of CSTF2 expression across multiple cancer types, including gastric cancer, was conducted using TCGA data. Immunohistochemistry for CSTF2 in collected gastric cancer and adjacent slices of normal tissue revealed that CSTF2 was overexpressed in cancerous tissue compared to normal tissue (Fig. 1A, B). RT‒qPCR analyses corroborated these findings at the RNA level (Fig. 1C). Survival analyses indicated that increased CSTF2 expression was linked to OS/DFS outcomes in the patient cohort (Fig. 1D). CSTF2 is abundantly present in gastric cancer. A Pancancer analysis showed that CSTF2 was highly expressed across diverse types of cancers, gastric cancer included. B Immunohistochemistry analysis of CSTF2 in gastric cancerous tissues and regular tissues. C CSTF2 RNA expression degrees in gastric cancer tissues and healthy specimens were compared. D OS/DFS curves analyzed by Kaplan–Meier method; differences assessed by log-rank test CSTF2 augments gastric cancer cell proliferation CSTF2 protein levels were measured in BGC-823 and MKN-28 cells following knockdown (Fig. 2A). This reduction led to impaired cell growth and colony development (Fig. 2B, C). In vivo xenograft models further validated the suppressive impact of CSTF2 knockdown on tumour growth (Fig. 2D). Furthermore, to investigate the impact of CSTF2 on metastatic potential, we performed transwell migration and invasion assays. Knockdown of CSTF2 significantly impaired the migratory and invasive capabilities of both BGC-823 and MKN-28 cells compared to the control groups (Fig. 3A, B), indicating that CSTF2 not only promotes proliferation but also drives the aggressive and metastatic behavior of gastric cancer cells. CSTF2 drives the expansion of gastric cancer tissues. A WB was used to assess CSTF2 protein degrees in gastric cancer specimens. B Proliferation patterns of BGC-823 and MKN-28 cells. C Assay for colony formation of BGC-823 and MKN-28 cells. D Tumour images and data obtained after stable transfection of gastric cancer specimens with shNC or shCSTF2 and xenografting. All the experiments were replicated at least thrice. A two-tailed independent t test was used. *P < 0.05 and ** P < 0.01. The number of technical replicates for cell experiments is ≥ 3 CSTF2 promotes migration and invasion of gastric cancer cells. A Cell migration assay of BGC-823 and MKN-28 cells. B Cell invasion assay of BGC-823 and MKN-28 cells. All experiments were independently repeated at least three times. Statistical significance was determined by a two-tailed independent t test (** P < 0.01) Downstream gene regulation by CSTF2 RNA sequencing revealed that the presentation of numerous genes was modified by CSTF2 knockdown, suggesting changes in chromatin dynamics and protein‒DNA interactions (Fig. 4A). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses highlighted the potential influence of CSTF2 on chromatin disassembly and cytokine receptor interaction pathways (Fig. 4B, C). CSTF2 regulates the expression of TGM2. A Volcano plot displays gene expression changes following CSTF2 inhibition. B GO analysis of differentially expressed genes after CSTF2 knockdown. C KEGG analysis of genes with changed expression intensity after CSTF2 knockdown CSTF2 influences TGM2 expression RNA sequencing revealed 15 genes whose expression was diminished both BGC-823 and MKN-28 cells (Fig. 5A). Anna Torres et al. [26] Studies have shown a significant increase in TGM2 expression in endometrial cancer. Furthermore, TGM2 is overexpressed in papillary thyroid carcinoma, and this phenotype is positively correlated with extrathyroidal invasion and lymph node metastasis [27]. Therefore, TGM2 was selected for further study. RT‒qPCR and WB analyses revealed that CSTF2 expression inhibition significantly attenuated the RNA and protein degrees of CSTF2 and TGM2 (Fig. 5B, D). The experimental results demonstrate that the association between CSTF2 and TGM2 is statistically meaningful, with a p value of 0.0059 (P < 0.001) (Fig. 5C). To elucidate the mechanism by which CSTF2 regulates TGM2, we first assessed the mRNA level of TGM2 upon CSTF2 knockdown. The result revealed that silencing CSTF2 destabilized TGM2 mRNA in both BGC-823 and MKN-28 cells (Fig. 5E). In gastric cancer tissues, immunohistochemical staining revealed that TGM2 expression was markedly elevated compared to the surrounding normal tissues (Fig. 5F). Screening of the downstream gene TGM2. A Venn diagram showing the number of downregulated genes after knockdown of CSTF2 in BGC-823 and MKN-28 cells, with 15 genes overlapping. B mRNA expression levels of CSTF2 and TGM2 after CSTF2 knockdown in different groups, as determined by qRT-PCR. C Spearman correlation analysis of the expression levels between CSTF2 and TGM2.D Protein expression levels of CSTF2 and TGM2 after CSTF2 knockdown, as assessed by western blotting. E BGC-823 and MKN-28 cells were treated with actinomycin D (10 ug/ml) and harvested at 0, 2, 4, 6, and 8 h for RNA extraction. TGM2 mRNA levels were measured by qPCR at the different timepoints, using GAPDH as input control. F Representative immunohistochemistry (IHC) images of TGM2 expression in gastric cancer tissues and adjacent normal tissues (magnification: 200x). All experiments were independently repeated at least three times. Statistical significance was determined by a two-tailed independent t test (*P < 0.05, **P < 0.01, ***P < 0.001) TGM2 enhances the proliferation and spread of gastric cancer tissues The shRNAs were transfected into BGC-823 and MKN-28 cells to inhibit TGM2 manifestation (Fig. 6A). Knockdown of TGM2 in these cells notably reduced proliferation and colony formation, highlighting its role in promoting gastric cancer cell growth (Fig. 6B, C). Similarly, the depletion of TGM2 also led to a dramatic reduction in cell migration and invasion in both cell lines (Fig. 7A, B), reinforcing the notion that TGM2 is a crucial effector molecule contributing to the aggressive phenotype of gastric cancer cells. Changes in cells with TGM2 knockdown. A Protein expression level after knockdown of TGM2. B Procreation of BGC-823 and MKN-28. C Colony establishment assay of BGC-823 and MKN-28. All the experiments were conducted three or more times. A two-tailed independent t test was used. The number of technical replicates for cell experiments is ≥ 3. ** P < 0.01 TGM2 knockdown inhibits the migration and invasion of gastric cancer cells. A Cell migration assay of BGC-823 and MKN-28 cells. B Cell invasion assay of BGC-823 and MKN-28 cells. Statistical significance was determined by a two-tailed independent t test (**P < 0.01) Effects of the interaction between TGM2 and CSTF2 To further dissect the relationship between CSTF2 and TGM2, cell lines with CSTF2 knockdown alone or CSTF2 knockdown with restoration of TGM2 were engineered. In the control group, both CSTF2 and TGM2 were expressed; in the lentivirus knockout CSTF2 group, the expression of CSTF2 was knocked out, and the extent of expression of TGM2 was also significantly decreased; TGM2 expression was significantly higher in the plasmid overexpression cluster compared to the control cluster; in the lentivirus knockout CSTF2 and plasmid overexpression TGM2 groups, CSTF2 was not expressed or the expression level was decreased, TGM2 was still expressed, but the expression level was lower than both the control and plasmid overexpression TGM2 groups. (Fig. 8A). Restoration of TGM2 expression in CSTF2-deficient cells partially rescued the proliferative and colony formation caused by CSTF2 knockdown, suggesting that CSTF2 promotes oncogenic traits in gastric cancer cells, at least in part, by modulating TGM2 expression (Fig. 8B, C). Rescue experiments. A Protein expression amounts of CSTF2 and TGM2. B Proliferation of BGC-823 and MKN-28. C Colony establishment assay of BGC-823 and MKN-28. Each experiment was conducted a minimum of three times to ensure accuracy. A two-tailed independent t test was used. The number of technical replicates for cell experiments is ≥ 3. ** P < 0.01 Discussion Our research strengthens the hypothesis that CSTF2 plays an influential role in gastric carcinogenesis. Immunohistochemical assays confirmed that CSTF2 expression was notably greater in gastric cancer specimens compared to neighboring non-cancerous samples. This overexpression also demonstrated a negative relationship with the OS/DFS of patients afflicted by gastric cancer. Notably, in BGC-823 and MKN-28 cells, CSTF2 knockdown via shRNA was found to drastically reduce tumour cell proliferation and colony formation ability. This antiproliferative effect was reflected by marked growth inhibition in our murine models of gastric cancer, suggesting that targeting CSTF2 might be a promising treatment strategy. Our findings also indicate that dysregulation of master molecular regulators drives cancer pathogenesis. Different classes of regulators, however, exert their effects through distinct mechanisms. Bicheng Ye and colleagues demonstrated that the transmembrane protein TMEM71 can inhibit the malignant phenotype of nasopharyngeal carcinoma by regulating the NLRP3/Caspase-1/GSDMD pathway [28]. Genes of the COMMDs family can promote the proliferation and migration of gastric cancer cells via the PI3K–AKT pathway [29]. In addition, studies on sphingolipid metabolism have shown that it can predict patient prognosis and further influence the efficacy of immunotherapy by regulating immune cell infiltration. [30] As a key mediator in this process, the ferroptosis-related gene CISD2 was demonstrated by Zhengrui Li et al. to regulate tumor radiosensitivity by modulating metal ion homeostasis, further illustrating how master regulators drive tumor malignant progression by acting on metabolic pathways [31]. This metabolic reprogramming mechanism parallels our finding that CSTF2 modulates TGM2-dependent pathways, suggesting RBPs may converge with ferroptosis regulators to orchestrate tumor progression. Furthermore, the interplay between genetic alterations and the tumor microenvironment is also a critical regulatory mechanism. Yizhen Chen et al. have found that oncogenic mutations such as KRAS in colorectal cancer can promote the intratumoral colonization of enterotoxigenic Bacteroides fragilis through the miR3655/SURF6/IRF7/IFNβ axis, thereby reshaping the tumor microenvironment. This underscores the close link between genetic alterations and microbial dysbiosis [32]. Nevertheless, RBPs represent a distinct tier of regulators, as they can modulate multiple pathways through post-transcriptional regulation. Echoing this theme, our previous work has elucidated similar themes. We identified that PCBP2 acts as a promoter of gastric cancer cell survival through its regulation of CDK2, indicating that RBPs often play multifaceted roles frequently have diverse functions in cancer biology [33]. Another RNA-binding protein, NELFE, has been shown to demonstrate oncogenic activity in gastric cancer partly via E2F2 [24]. Expanding the scope of such proteins, Marco Pieraccioli et al.'s study revealed that Sam68 cells defy expression norms, inhibiting proliferation and G1/S cell division cycle progression in prostate cancer [34]. Much of the earlier focus on CSTF2 pertained to its crucial function during mRNA precursor cleavage. Yanfen Zheng et al. reported the contribution of CSTF2 to pancreatic ductal adenocarcinoma subtyping through N6-methyladenosine (m6A) modification [35], while Shijie Chen et al. reported a similar role in osteosarcoma, revealing a negative relationship between CSTF2 expression and patient outcome [36]. This study provides new insight into how CSTF2 acts as an oncogenic driver in gastric cancer via downstream gene regulation. Among the downstream genes, we identified TGM2 as a research target by RNA sequencing. TGM2 is an enzyme involved in cellular function regulation and signalling that has a major impact on cancer development and can contribute to the onset and advancement of a variety of cancers [37, 38]. Ping Yang et al. [39]reported that TGM2 can participate in the modulation of colorectal cancer through Wnt/β-linker proteins. Shan Zhang [40] found that in pancreatic cancer, TGM2 can promote macrophage infiltration into the tumour microenvironment, thereby promoting tumour progression. According to RNA sequencing after knockdown of CSTF2, TGM2 was the most downregulated gene in terms of the degree of change. Immunoblotting experiments after the inhibition of CSTF2 expression suggested that the amount of the protein expressed of TGM2 was appreciably lowered, consistent with the results at the RNA level. Further experiments showed that TGM2 expression was higher in gastric cancer than in normal stomach specimens. By performing TGM2 knockdown experiments in BGC-823 and MKN-28 cells, we found that the proliferation and colony-generation capability of tumour cells was effectively inhibited. The conclusions of the rescue experiments suggested that overexpression of TGM2 blocked the effects of reduced cell proliferation and colony formation caused by CSTF2 knockdown. Our functional experiments revealed that knockdown of either CSTF2 or its downstream effector TGM2 significantly suppressed the migration and invasion capabilities of gastric cancer cells. These results indicate that the CSTF2–TGM2 axis contributes comprehensively to tumor progression by enhancing both proliferative and metastatic behaviors—key drivers of poor prognosis in gastric cancer patients. Importantly, the RNA half-life demonstrated that CSTF2 knockdown markedly accelerated the decay of TGM2 mRNA, indicating that CSTF2 post-transcriptionally regulates TGM2 by enhancing its mRNA stability. Sung-Yup Cho et al. reported [41] that in the gastric cancerous tissues, TGM2 expression was markedly increased, and that the expression degree was closely correlated with an increase in tumour-associated inflammation. It has also been demonstrated that overexpression of TGM2 can lead to an increase in the stability of STAT1, which drives the expansion and penetration of gastric cancer tissues [42]. Taken together, the comprehensive body of evidence from in vitro and in vivo analyses positions CSTF2 as an oncoprotein that propagates gastric cancer progression via the specific regulation of TGM2. Our findings indicate that CSTF2 overexpression is associated with poorer OS and DFS in gastric cancer patients. The upregulation of its downstream effector, TGM2, further supports their collective role as prognostic biomarkers. This observation aligns with the broad clinical translational value of biomarkers. Pan-cancer analysis has demonstrated that immune-inflammatory scores such as PIV and mGPS can serve as independent predictors of survival in patients with colorectal cancer and breast cancer [43, 44]. Functionally, knockdown of either CSTF2 or TGM2 inhibits cell proliferation and tumor growth, establishing the CSTF2–TGM2 axis as a potential therapeutic target. Within the broader strategy of targeting RBPs in oncology, the appeal of such approaches lies in their cancer-specific expression and multifunctional regulation of oncogenic pathways. However, key challenges remain, including delivery obstacles for RBP-targeting agents and potential off-target effects resulting from their broad RNA-binding activity. To overcome these inherent challenges and enhance treatment efficacy, combination strategies may prove essential. Studies by Yizhen Chen et al. have shown that a therapeutic regimen combining chemotherapy with anti-angiogenic agents exhibits favorable efficacy in high-risk colorectal cancer patients [45]. Therefore, a combined therapeutic approach integrating CSTF2-targeted therapy with existing treatment modalities may represent a promising strategy for improving therapeutic outcomes. This study used cellular and animal models as research platforms, but the findings have not yet validated its findings in a wider range of clinical samples; therefore, sufficient proof of clinical relevance is lacking. In addition, although the study highlighted the significance of TGM2 in gastric cancer, the molecular mechanism through which the CSTF2–TGM2 axis specifically promotes tumour formation and progression has been inadequately described, and the detailed of signalling process has not been fully characterized. Conclusions This study discovers the crucial function of CSTF2 in gastric cancer and recognizes CSTF2 as an alternative therapeutic focus. In addition, it is found that TGM2 acts as a downstream effector of CSTF2, but further research is needed to deepen these findings. Acknowledgements We express our gratitude to AJE (https://www.aje.cn) for their English proofreading and revision services. Author contributions Liang Feng: Data curation, Writing – original draft, Writing – review & editing. Zhiguo Cao: Data curation, Investigation, Funding acquisition. Xiaoqi Shi: Data curation, Investigation, Methodology. Wenhao Liu: Data curation. Weiwei Xu: Writing – original draft. Changjun Yu:Project administration, Supervision, Funding acquisition. Jie Ning: Project administration, Supervision. Changyu Chen: Conceptualization, Funding acquisition, Project administration, Supervision. Funding 1. The Natural Science Research Project of Anhui Higher Education Institution (2022AH051174, KJ2021A1363, KJ2021ZD0025). 2. Research Fund of Anhui Institute of translational medicine (2022zhyx-C69. 3. Academic Assistance Project for Top Talents in Anhui Colleges and Universities (gxbjZD2022125). 4. Academic Teaching Master Teacher Project of Anhui Health Career College (2022YJJSPY02). Data availability The data that support the findings of this study are available on request fromthe corresponding author. Declarations Ethics approval and consent to participate This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Anhui Medical University under the ethical approval number Quick-PJ 2021-09-07. Informed consent Informed consent was obtained from all subjects involved in the study. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Liang Feng, Zhiguo Cao, and Xiaoqi Shi are contributed equally to this work. Contributor Information Jie Ning, Email: nj830921@126.com. Changyu Chen, Email: chenchangyu1987@163.com. References Associated Data Data Availability Statement The data that support the findings of this study are available on request fromthe corresponding author.